Stay updated on SNDX-5613 in R/R Leukemias: Clinical Trial

Sign up to get notified when there's something new on the SNDX-5613 in R/R Leukemias: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SNDX-5613 in R/R Leukemias: Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    A new revision tag (v3.5.4) has been added and the previous revision (v3.5.3) removed, indicating a platform update that does not alter the study details on the page.
    Difference
    0.0%
    Check dated 2026-05-17T10:22:26.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    41 days ago
    Change Detected
    Summary
    The page footer revision was updated from v3.5.0 to v3.5.3, indicating a site/about-page version display change rather than any modification to the clinical trial information.
    Difference
    0.0%
    Check dated 2026-04-25T18:34:14.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Added the March 2026 Mol Cell Proteomics publication 'High-Throughput Proteomic Profiling to Evaluate Differentiation Syndrome With Menin Inhibition' (doi:10.1016/j.mcpro.2026.101522). Removed the January 2026 'Online ahead of print' listing for the same article.
    Difference
    0.0%
    Check dated 2026-04-04T05:44:40.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The study record was updated to add numerous sites and investigators with updated contact details, and several former contacts were removed.
    Difference
    4%
    Check dated 2026-03-20T20:18:29.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    Added a new publication citation (Mol Cell Proteomics, 2026) and updated the page revision to v3.4.3; the prior citation was removed (v3.4.2).
    Difference
    0.0%
    Check dated 2026-03-06T18:07:16.000Z thumbnail image
  9. Check
    105 days ago
    Change Detected
    Summary
    Phase 2 expansion cohorts increased from 3 to 4 with the addition of Cohort 2D (HOX/MEIS upregulation leukemias, including KMT2Ar, NPM1m, and NUP98r) and the enrollment target is updated to 447. Key inclusion/exclusion criteria were added or revised (e.g., CNS prophylaxis allowed, concurrent cytoreductive therapies permitted, and other drug interactions) to reflect new eligibility and concomitant therapy guidelines.
    Difference
    1%
    Check dated 2026-02-20T17:03:13.000Z thumbnail image

Stay in the know with updates to SNDX-5613 in R/R Leukemias: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SNDX-5613 in R/R Leukemias: Clinical Trial page.